1784.Two
1784.TWO operates in the healthcare diagnostics industry, providing diagnostic solutions and related services to healthcare providers and patients.
Business. 1784.TWO operates in the healthcare diagnostics industry, providing diagnostic solutions and related services to healthcare providers and patients.
Analyst recommendations
1 analysts · consensus HoldAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
1784.TWO operates in the healthcare diagnostics industry, providing diagnostic solutions and related services to healthcare providers and patients.
1784.TWO maintains a relatively strong liquidity position, with a current ratio of 4.62, indicating the company can cover its short-term liabilities more than four times over with its current assets. However, the company's free cash flow is negative at -139,066,000 TWD, and capital expenditures are also negative at -132,184,000 TWD, suggesting significant investment in long-term assets. The company's cash and equivalents amount to 73,932,000 TWD, but this is offset by long-term debt of 113,802,000 TWD, resulting in a net cash position that is negative after subtracting total debt.
Profitability metrics for 1784.TWO show a return on equity of 4.04% and a return on assets of 1.67%. These figures are below the industry median for return on equity and return on assets, indicating that the company is underperforming its peers in terms of generating returns from equity and total assets. The company's operating income is negative at -14,384,000 TWD, while net income is positive at 51,426,000 TWD, suggesting that non-operating income or gains are contributing to profitability.
The company's revenue is concentrated in a single segment, as no additional segments are disclosed in the financial data. Geographically, the company's exposure is primarily within its domestic market, with no specific international revenue breakdown provided. This concentration may pose a risk if the domestic market experiences economic downturns or regulatory changes.
Looking at the company's growth trajectory, the current fiscal year is expected to see a slight decline in revenue, with analyst estimates projecting 1,220,000,000 TWD compared to the current revenue of 1,236,596,000 TWD. The next fiscal year is also expected to show a modest decline, with no significant growth anticipated. The company's operating cash flow is positive at 148,040,000 TWD, which supports its operations and helps fund capital expenditures.
Risk factors for 1784.TWO include a medium liquidity risk, as indicated by the negative net cash position after subtracting total debt. The company's dilution risk is low, with no significant dilution potential reported. However, the negative free cash flow and capital expenditures suggest that the company may need to seek additional financing in the future, which could lead to increased debt or equity dilution.
Recent events and filings do not indicate any major changes or risks for the company. The company's financial performance and strategic direction appear to be stable, with no significant events reported in the latest filings or transcripts.
- 1784.TWO has a strong current ratio but faces challenges with negative free cash flow and capital expenditures.
- The company's return on equity and return on assets are below industry medians, indicating underperformance in profitability.
- Revenue is concentrated in a single segment, and geographic exposure is primarily domestic, which may increase risk.
- Analyst estimates suggest a slight decline in revenue for the current and next fiscal years.
- The company has a medium liquidity risk and a low dilution risk, but may need additional financing in the future.
- "margin_outlook_rationale": "The company's operating income is negative, indicating potential margin pressures from rising costs or declining prices.",
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 1784.TWO Market data — financials · 2026-05-26
- Bionet Corp Market data — analyst estimates · 2026-05-26